Health Care Supplies

Dentsply Sirona

Dentsply Sirona released FY2026 Q1 earnings on May 5 During-Market EST, actual revenue USD 880 M (forecast USD 840.08 M), actual EPS USD -0.05 (forecast USD 0.0347)

Dentsply Sirona to release FY2026 Q1 earnings on May 5 During-Market EST, forecast revenue USD 841.77 M, EPS USD 0.0347

Dentsply Sirona and Siemens Healthineers Receive FDA Approval for Dental MRI System

DENTSPLY SIRONA Inc. Director Buys Shares

Dentsply Sirona director James D. Forbes purchases 5,000 company shares

DENTSPLY SIRONA updates 2026 fiscal year earnings guidance

Dentsply Sirona Misses Q4 Earnings Estimate

Dentsply Sirona Reports Earnings and Announces Restructuring Plan

Dentsply Sirona expects net sales of $3.5 billion to $3.6 billion for fiscal year 2023

Dentsply Sirona released FY2025 annual earnings on February 26 During-Market (EST), actual revenue USD 3.68 B (forecast USD 3.645 B), actual EPS USD -3 (forecast USD -2.2119)

Dentsply Sirona released FY2025 Q4 earnings on February 26 During-Market EST, actual revenue USD 961 M (forecast USD 926.37 M), actual EPS USD -0.7314 (forecast USD 0.0188)

Dentsply Sirona to release FY2025 Q4 earnings on February 26, 2026, during market hours (EST), forecast revenue USD 926.4 M, EPS USD 0.0188

Dentsply Sirona Releases New Presentation Outlining Market Segments and Product Innovations

Evercore ISI Maintains DENTSPLY SIRONA's Hold Rating with a Price Target

DENTSPLY SIRONA Renews Distribution Agreement with Patterson Dental

Dentsply Sirona Showcases Leadership in Dental and Digital Solutions at JPM Healthcare Conference

Dentsply Sirona and Benco Dental Expand Partnership to Enhance Digital Dental Solutions Distribution

Dentsply Sirona Publishes Study on Reciproc Root Canal Treatment Scheme Increasing Tooth Survival Rates

Dentsply Sirona released FY2025 9 Months Earnings on November 6, Pre-Market EST: Actual Revenue USD 2.719 B, Actual EPS USD -2.2661

Dentsply Sirona released FY2025 Q3 earnings on November 6 Pre-Market EST, actual revenue USD 904 M (forecast USD 897.73 M), actual EPS USD -2.1403 (forecast USD 0.1762)

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

XRAY

Dentsply Sirona will present at the Stifel Jaws & Paws Conference on May 27, 2026, at 3:35 p.m. ET.

PUBT

Dentsply Sirona to present at Stifel Jaws & Paws Conference

Dentsply Sirona (XRAY) reported Q1 2026 revenue of $880 million with a basic EPS loss of $0.05 and a net income loss of $10 million. Despite a narrower loss compared to previous periods, the company faces challenges with profitability and slow revenue growth of 1.2% per year. Analysts highlight a low price-to-sales ratio of 0.6x, but ongoing losses and a 5.75% dividend yield raise concerns about cash generation. The mixed outlook emphasizes the need for margin recovery to support future earnings and dividend coverage.

Simplywall

Dentsply Sirona (XRAY) Narrower Q1 Loss Tests Bullish Margin Recovery Narrative

Dentsply Sirona's Q1 earnings call highlighted operational progress amid near-term challenges. Revenue remained flat at $880 million, with a 6.7% decline in constant currency. Management reaffirmed 2026 guidance of $3.5–$3.6 billion in net sales. Operating cash flow improved to $40 million, supporting debt reduction efforts. Despite some growth in specific segments, overall constant-currency sales fell, and adjusted EBITDA margins contracted due to lower volumes and unfavorable sales mix. Tariffs and macroeconomic uncertainties pose additional risks to profitability and demand.

Tip Ranks

Dentsply Sirona Earnings Call Balances Progress and Pain

Citi analyst Daniel Grosslight has maintained a Sell rating on DENTSPLY SIRONA (XRAY) with a price target of $10.50. This follows a similar Sell rating from Barclays analyst Glen Santangelo. Conversely, Piper Sandler has reiterated a Hold rating on the stock. Grosslight has an average return of 2.1% and a 44.33% success rate on his stock recommendations, focusing on the Healthcare sector.

DENTSPLY SIRONA (XRAY) Receives a Sell from Citi

Dentsply Sirona (NASDAQ:XRAY) reported its Q1 2026 earnings, focusing on sustainable growth initiatives and strategic priorities. The company is enhancing clinical education and salesforce training, with positive early feedback. Key efforts include returning the US to growth, focusing on the implant business, and increasing R&D investments. Recent product launches aim to improve diagnostic capabilities. Dentsply is restructuring for $120 million in annual savings and has reduced debt by $80 million. Management remains cautious but optimistic about consistent execution and growth in the latter half of the year.

Dentsply Sirona(XRAY.US)

Dentsply Sirona to present at Stifel Jaws & Paws Conference

Dentsply Sirona (XRAY) Narrower Q1 Loss Tests Bullish Margin Recovery Narrative

Dentsply Sirona Earnings Call Balances Progress and Pain

DENTSPLY SIRONA (XRAY) Receives a Sell from Citi

Dentsply Sirona Q1 2026 Earnings Call Transcript

Dentsply Sirona | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 880 M

Dentsply Sirona | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 880 M